Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a Healthcare company (Biotechnology) with a market capitalization of $3.5B. The Maz Rating grades it against the other companies in its sector.
Iovance Biotherapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.55, Iovance Biotherapeutics, Inc. trades at 9.2x sales and 4.2x book value. Over the last twelve months it generated about $379M of revenue and a net loss of $245M. It runs a gross margin of 53.2%, an operating margin of -60.8% and a net margin of -58.2%. It shows return on equity of -29.7%, return on invested capital of -25.8% and a free cash flow yield of -6.2%. On the balance sheet: a debt-to-equity ratio of 0.06 and a current ratio of 5.20. Over the past 52 weeks the share price ranged from $2.08 to $15.37, with a beta of 0.76.
Iovance Biotherapeutics, Inc. does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 15 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.